Clinical-stage oncology biotechnology; focus on targeted immuno-oncology and precision medicine for hematologic malignancies and solid tumors
Strategic Profile
Curis is a clinical-stage biotechnology company advancing targeted therapies for cancer treatment, with a focus on immuno-oncology and precision medicine. The company's lead asset, emavusertib, an IRAK4 inhibitor, recently showed a promising 50% MRD conversion rate in a July 2025 data cut-off for its AML triplet study, a critical clinical milestone that could dramatically change its valuation.
Cyborg Score Rationale
Curis shows compelling clinical progress with emavusertib's promising data, but faces significant near-term capital constraints ($9.1M cash as of Sept 2025) and a severely depressed valuation (~$13-18M market cap). The company is highly dependent on successful clinical advancement and continued funding access, creating high execution risk despite strong science.
Top Insights
Pure-play transition: Eliminated legacy Erivedge royalty income ($3.2M quarterly) in November 2025 to strengthen balance sheet, now entirely pipeline-dependent
Lead candidate momentum: Emavusertib achieved 50% MRD conversion in AML triplet combination trial (July 2025 data), supporting potential accelerated approval pathway in R/R PCNSL
Severe capital constraints: Only $9.1M cash position with operating burn of ~$7-10M quarterly; multiple recent financings required despite dilution
Depressed valuation: Trading at ~$13.4M market cap (Feb 2026) on ~12.9M shares with 1-year analyst target of $14/share, suggesting massive upside if clinical wins occur
Named Competitors
Opzelura/Ruxolitinib — JAK inhibitor for cutaneous T-cell lymphoma; competitive immuno-oncology play
Checkpoint inhibitors (PD-1/PD-L1/CTLA-4) — Established immuno-oncology standard of care; large pharma competition
HDAC inhibitors — Competing HDAC/epigenetic modulation approaches for lymphomas
Recent Developments
(November 2025) Sold remaining Erivedge royalty interest for $2.5M, extinguishing $28.6M liability; transitioned to pure-play biotech
(July 2025) Emavusertib showed 50% MRD conversion rate in AML triplet combination study with venetoclax/azacitidine
(May 2025) Q1 2025 results: net loss improved to $10.6M from $11.9M YoY; completed $8.8M financing; CMO appointment (Dr. Ahmed Hamdy from Pharmacyclics)
Open the full interactive Curis, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.